Wuxi Biologics Has Announced A Global Strategic Partnership With Pharmadule Morimatsu For Its Singapore-Based Contract Development And Manufacturing Organisation (Crdmo) Centre Project.The Partnership Between Pharmadule Morimatsu And Wuxi Biologics Provides Modular Facilities For The Wuxi Biologics Singapore Crdmo Centre Project. This Collaboration Aims To Support Wuxi Biologics In Expanding Its Production Capacity, Accelerating The Empowerment Of Global Pharmaceutical Companies, Reducing Research And Development (R&D) Costs, And Ultimately Benefiting Patients Worldwide.The Collaboration Between The Singapore Crdmo Centre And Pharmadule Morimatsu Allows To Leverage Their Expertise And Experience In Establishing Global Sites Successfully Demonstrated By The Greenfield Site In Ireland, Further Enhancing The Ability To Serve Global Partners With Premier Quality Services And Solutions.The Crdmo Centre In Singapore Adopts New Generation Of Modular Fabrication And Perform The Majority Of Construction Work At Morimatsu'S Workshop And Brings Several Advantages In Terms Of Quality, Schedule, Cost, And Risk Management.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!